Compare Infosys Limited (INFY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Novartis AG — how do they compare? Infosys Limited trades at $10.71 (market cap $41.74B), while Novartis AG trades at $142.74 (market cap $268.57B). The key difference: Novartis AG is far larger — about 6.4× Infosys Limited's market cap, and Infosys Limited pays the higher dividend (4.89%). Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Novartis AG for 82 Days on average.
| INFY | NVS | |
|---|---|---|
Market Cap | $41.74B | $268.57B |
Volume | 31,354,285 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $20.22 | $168.62 |
52-Week Low | $10.49 | $121.80 |
Typical Hold Time | 27 Days | 82 Days |
Enterprise Value | $39.48B | $309.89B |
Dividend Yield | 4.89% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Infosys (INFY) trades at $10.55, showing no change in the latest session. The stock is in a bearish technical trend with key support at $10 and resistance at $11. Fundamentally, the company reported strong profitability with a net income margin of 16.37% and ROE of 32.12% for 2025. Recent news highlights strategic AI collaborations, including with Columbia University and ABN Amro, to drive innovation. However, cash flow trends show a projected decline in net cash flow for 2026.
The outlook for INFY is mixed. Positive fundamentals and strategic partnerships offer growth potential, but bearish technicals and a projected cash flow decline pose risks. Analyst consensus is a 'Hold' with a price target of $11.48, suggesting limited near-term upside. Investors should weigh strong profitability against execution risks in a competitive IT services market.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
